30 closest matches · ranked by relevance
Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Primary: Number of Participants Who Had One or More Adverse Events (AE) and Serious Adverse Events (SAE) — 238; 97 Participants
Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic
Primary: Overall Response Rate (ORR) — 70.0; 66.7 percentage of participants
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Lymphoma
Primary: Objective Response Rate (ORR) — 64 percentage of participants
Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) Based on the Assessments by Investigator — 8.8; 36.8; 45.6 percentage of participants
Hodgkin Lymphoma · Anaplastic Large-cell Lymphoma
Primary: Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose — NA; NA; NA; NA ng/mL
Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 50 percentage of participants
Anaplastic Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Number of Patients With Response — 0; 2 participants
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Recurrent Lymphoproliferative Disorder · Refractory Lymphoproliferative Disorder
Primary: Overall Response Rate — 0 percentage of participants
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Number of Participants With Overall Response (OR) — 15; 4 participants
Hodgkin Lymphoma, Adult
Primary: ORR Assess by IRC — 76.0 percentage
Peripheral T Cell Lymphoma · Transformed Mycosis Fungoides
Primary: Overall Response Rate Assessed by Independent Review Committee Based on PET-CT — 32.4 percentage — p=0.051
Hodgkin Disease
Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants
Classical Hodgkin Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months
Peripheral T Cell Lymphoma · Pediatric Hodgkin Lymphoma
Primary: Percentage of Participants Who Had One or More Serious or Non-serious Adverse Event Classified as Peripheral Neuropathy — 0; 0; 0; 0 Participants
T-cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepato-splenic T-cell Lymphoma
Primary: Overall Response Rate — 89.5 percentage of participants
Anaplastic Large Cell Lymphoma, ALK-Positive · Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma · Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Primary: Occurrence of Grade 3+ Non-hematologic Adverse Events — 80.6; 87.9 Percentage of patients
Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Acute Lymphoid Leukemia · Acute Myeloid Leukemia · Anemia, Refractory, With Excess of Blasts
Primary: Objective Response Rate (ORR) by Investigator — 12; 14 percentage of participants
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Maximum Tolerated Dose of Brentuximab Vedotin That Can be Combined With Ifosfamide, Carboplatin, and Etoposide Chemotherapy — 1.5 mg/kg
Lymphoma, B-Cell · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Non-Hodgkin
Primary: Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy — 41; 26; 44; 31 percentage of participants
Lymphoma, Large-Cell, Anaplastic · Lymphoma, Non-Hodgkin
Primary: Objective Response Rate by Independent Review Group — 86 percent of participants
Hodgkin Lymphoma
Primary: Number of Participants With Adverse Events (AEs) — 6; 55; 30; 5 Participants
Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) — 25.00; 37.50; 75.00; 62.50 percentage of patients
Hodgkin Lymphoma
Primary: Overall Response Rate — 20.0 percentage of participants
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Complete Response (CR) Rate — 0; 36 percent of participants
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Lymphoma, T-Cell, Cutaneous
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 1; 0; 0; 0 Participants
Lymphoma
Primary: Objective Response — 3; 6; 3; 2 participants